Summary Type A prostaglandins (PGA, and 16,16-dimethyl-PGA2-methyl ester) were found to block the proliferation of HTLV-I infected cord blood lymphocytes (CBL) in vitro, thus preventing the clonal immortalisation that is considered as a predisposing condition to HTLV-I positive leukaemia. PGA, and di-M-PGA2 did not affect the long-term survival of normal non-infected CBL, whereas they suppressed the proliferation of an established cord-blood derived HTLV-I positive cell line, MT-2. As shown by the number of HTLV-1 infected pl9+ cells, the block of the selection of immortalised, infected clones by PGAs did not appear to be due to an inhibition of early stages of HTLV-I infection. The possibility that the effect of PGAs could be mediated by an action on the immune response was also examined. PGAs regulated the cell-mediated cytotoxic function of CBL to a different extent when normal non-infected or HTLV-I exposed CBL were compared. In fact, PGAs down-regulated the natural killing and macrophage/lymphocyte cytotoxic response of normal CBL, whereas they did not modify the already depressed immune response of CBL challenged with HTLV-I. These results suggest that the protective effect of PGAs against HTLV-I infection in vitro is mostly related to the direct suppression of the clonal expansion of virus-infected cells, rather than to the anti-viral activity or modulation of the cell-mediated immunity.
Human T-cell leukaemia/lymphoma virus type I (HTLV-I) is an oncogenic retrovirus that was found to be involved in the transformation of CD4+ lymphocytes into malignant leukaemic cells both in vivo and in vitro (Wong-Staal & Gallo, 1985) . Transformation can occur after integration of the HTLV-I provirus in the host genome and requires a variable latency period before the appearance of the leukaemic state. Active virus replication does not seem to be required at this stage to maintain the transformed phenotype , whereas it is relevant in the early phase of infection.
Although the worldwide distribution of HTLV-I positive leukaemia is at present restricted to defined geographical areas (Gallo, 1985; Manzari et al., 1985; Yoshida, 1987) , the possibility of counteracting pharmacologically the spreading of infection in the future mainly relies on the understanding of the mechanisms of infection and virus-induced transformation. Specific inhibitors of the HTLV-I replicative cycle are very attractive, because they could be effective early, before the clonal selection of HTLV-I transformed lymphocytes. On the other hand, agents that can potentiate the host immunosurveillance against virus-infected cells might also help to overcome first the spreading of virus particles and later the survival of leukaemic cells.
Type A prostaglandins (PGAs) have been shown to possess both anti-viral and anti-proliferative properties. Dose-dependent anti-viral activity was demonstrated in the case of PGA, and PGA2 in a number of viral infections both in vitro (Santoro, 1987; Santoro et al., 1980) and in vivo (Santoro et al., 1988) . The highest effective concentration (4 .g ml-') was not toxic to cultured cells and in the case of Sendai virus (Santoro et al., 1981) it prevented the establishment of persistent infection. The mechanism of the antiviral action is not yet known, but in most models studied PGA treatment induced alterations in the synthesis and/or maturation of specific virus proteins (Santoro, 1987) . In addition to their anti-viral activity, PGAs can suppress the rate of tumour cell proliferation and promote cell differentiation in a large number of systems (Olsson et al., 1982; Santoro, 1987; Santoro et al., 1986; Santoro & Jaffe, 1989) , in some cases by potentiating the effect of other inducers, such as retinoic-acid (Olsson et al., 1982) . In human K562 erythroleukaemia, the anti-proliferative activity of PGAs is associated with the induction of a p74 cellular protein and the suppression of at least two proteins, p92 and p46 (Santoro et al., 1986) . Moreover, prostaglandins (PGs) are known to be involved in the regulation of the immune response in tumour-bearing hosts (Bayley & Fletcher-Cientat, 1987; Bonta & Ben Efraim, 1987) .
These combined effects of PGs were highly suggestive for possible modulating effects of PGAs in HTLV-I infection and transformation. In the present human model of virusinduced leukaemogenesis, infection can be obtained in vitro by co-culturing permissive target cells with a lethally irradiated HTLV-1 donor tumour cell line, thus allowing study of all the intermediate steps from infection to immortalisation.
Multiple treatments of these co-cultures with 4 tg ml-' PGA, or the PGA2 analogue 16,16-dimethyl-PGA2-methyl ester did not inhibit early stages of virus infection. However, at later stages the selection of immortalised clones was impaired by PGA treatment, as a consequence of the reduced proliferation rate of HTLV-I infected lymphocytes, which showed a survival pattern comparable to that of non-infected controls.
Materials and methods

Cell cultures and infection
Human mononuclear cells (CBL) were isolated from heparinised neonatal umbilical cord blood by Ficoll-hypaque gradients (Pharmacia, Uppsala, Sweden) and cultured in 24-well tissue culture plates or 25 cm2 flasks (Falcon, Oxnard, USA) in RPMI 1640 culture medium (Gibco, Grand Island, USA) supplemented with 20% heat-inactivated fetal calf serum (Gibco), 2 mM glutamine (Gibco), 100 U ml-' penicillin/ streptomycin, and 20 U ml-' recombinant interleukin 2 (IL-2, kindly provided by Hoffmann-La Roche, Basel, Switzerland) . For macrophage cultures, supplemented McCoy's 5 A medium (Gibco), enriched with bovine embryo extracts (Difco, Detroit, USA) (D'Onofrio & Paradisi, 1983) and without addition of IL-2, was used.
K562 human erythroleukaemia (Lozzio & Lozzio, 1975 ) and the HTLV-I donor MT-2 cells, a cord blood CD4 + established human cell line (Miyoshi et al., 1981) , were also grown in supplemented RPMI 1640 culture medium, in the absence of IL-2.
Freshly isolated CBL were infected in vitro by co-culture with lethally irradiated MT-2 cells (12,000 Rad) at a CBL/ MT-2 ratio of 5:1 (Akagi et al., 1985) . CBL/MT-2 co-cultures Correspondence: C. D'Onofrio.
were routinely grown in supplemented RPMI 1640 medium, containing 20 U ml-' IL-2. The culture medium was renewed every week without splitting the co-culture until the concentration of cells growing exponentially reached 106 cells ml-', around 6 weeks post infection (p.i. Irradiation of MT-2 cells in vitro MT-2 (HTLV-I+) cells were irradiated in vitro with 12,000 Rad using a '37Cs irradiator (Gamma Cell 1000, model A, AECL, Canada) delivering gamma rays at a rate of 1,000 rad min-', suspended in culture medium in 50 ml tubes at a concentration of 106 cells ml-'. The cells were then washed twice, resuspended in the culture medium and kept at 4°C until used. (Chirgwin et al., 1979) . For dot blots, 3 jig DNA or RNA samples were spotted on nitrocellulose filters (Schleicher & Schiill, Dassel, FRG) . DNA was denatured and neutralised before spotting according to Kafatos et al. (1979) . RNA samples were dissolved in 1 volume H20 + 1 volume 20 x SSC solution + I volume formaldehyde, denatured by heating at 65°C for 10 min and spotted on filters previously equilibrated in 20 x SSC. All filters were air-dried and baked for 2 h at 80°C.
Hybridisation was performed by using a 32P-nick-translated probe corresponding to the SstI-SstI fragment of the HTLV-I genome, isolated from the pMT-2 plasmid (kindly given by R.C. Gallo). This 8.5 kb fragment accounts for almost the entire HTLV-I genome. Nitrocellulose filters were hybridised for about 20 h in 10 x Denhardt's solution, 4 x SET and 0.1% SDS as described by Graziani et al. (1987) Indirect immunofluorescence for the phenotype markers of CBL/MT-2 co-cultures Anti-Leu 2a (CD8), Leu 3a (CD4), Leu 4 (CD3), Leu M3 and IL-2 receptor (CD25) monoclonal antibodies were purchased by Beckton and Dickinson (Milan, Italy) and used in the indirect test for immunofluorescence under routine conditions. FITC-conjugated anti-mouse F(ab')IgG were purchased from Bio-Yeda (Rehovot, Israel) and anti-mouse IgM (g) from KPL (Gaithesburg, USA). Air dried samples were fixed for 20 min in ethanol/acetic acid (9:1) at -20°C, rehydrated by washing twice with cold PBS (phosphate buffered saline pH 7.2) and stored at 4°C after being covered with glycerol and cover slips. An average of 600 cells was scored for each duplicate sample and the percentages of positive cells were compared by x2 analysis.
Assay for the cell-mediated cytotoxicity of whole CBL or macrophages The natural killer (NK) activity of CBL was tested on day 0 against the NK-susceptible K562 target cells at graded effector/target cell ratios (E/T; 100:1, 50:1, 25:1 12.5:1) in a 4 h 5'Cr-release assay under routine conditions (Graziani et al., 1987) . CBL were pretreated overnight with 4 jig ml-' PGA, or di-M-PGA2. The natural and antigen-specific cellular cytotoxicity of PGA-treated CBL, co-cultured with MT-2 cells, were respectively tested on day 7 p.i. against labelled K562 or MT-2 target cells in a 4 h 51Cr-release assay. In two separate experiments, cytotoxicity was evaluated on CBL subpopulations isolated by a double adherence step. Nonadherent cells (mostly lymphocytes, Ly) and adherent cells (mostly monocytes, Mo) were separately treated with PGA (4 fig ml ' ) and tested on days 0 and 7 for cytotoxicity against the NK-sensitive target K562 cells and the HTLV-I donor MT-2 cells in a 4 h 5'Cr-release assay using 20:1, 10:1 and 5:1 E/T ratios. Alternatively, lymphocytes were infected by co-culture with irradiated MT-2 cells under standard conditions and added as inhibitory cells to autologous 7-day-old macrophages (Mp) (1:1 ratio) pretreated (or not) with 4 fig ml-' PGAI for 1 week, before testing for cell-mediated cytotoxicity against K562 or MT-2 targets.
Per cent cytotoxicity was calculated according to the formula:
% specific lysis= c.p.m. sample release -c.p.m. autologous release total c.p.m.
x 100 and dose-response curves were obtained by plotting the percentages of specific 5'Cr-release of different E/T ratios (Thorn & Henney, 1976 ) and the number of killed cells (KC) per million effector cells was calculated. Significance (P) was calculated by regression test analysis.
Results
Effect of PGA treatment on in vitro infection of CBL with HTL V-I Non-stimulated human CBL can be kept in culture in the presence of IL-2, in the condition described in the Methods section, for 4-6 weeks. During the first week of culture, DNA synthesis of CBL, measured by 3H-thymidine incorporation, was very low when the cells were cultured in the absence of IL-2. When 20 U ml-' IL-2 were added to the medium, as routinely used for long-term lymphocyte cultures (Akagi et al., 1985) , isotope incorporation progressively increased and peaked in the first week of culture (data not shown). Graded amounts of PGAs (O.5-4 ttg ml-') added to IL-2 supplemented CBL cultures every 4 days until the fourth week did not significantly decrease cell number and viability. However, the marked increase of 3H-thymidine incorporation induced by the presence of IL-2 and herein described was depressed by approximately 50% by PGA, (4 igml-') addition (data not shown). This discrepancy between cell number and thymidine incorporation would reflect a different balance between cell proliferation and death of selected CBL subpopulations under the influence of IL-2 alone or IL-2 + PGA,. No early peak of 3H thymidine incorporation was detected when CBL were co-cultured with MT-2 cells, in spite of IL-2 supply (data not shown).
When cord-blood derived (HTLV-I + ) MT-2 cells were treated with PGAs, a dose-dependent inhibition of cell proliferation was obtained. A single PGA treatment (4 jg ml-') was effective in inhibiting proliferation (seeded at a density of 10' cells ml-' in 24-well plates, 2 ml per well) for 72 h, without significantly altering cell viability (at 72 h control 4.19 ± 0.08 x 105 cells ml-'; PGA, 1.65 ± 0.15 x 105 cells ml-'; viability 96%). PGA, concentrations lower than I jAg ml1' had no effect, whereas concentrations higher than 1OiLg ml-completely prevented cell replication, but were toxic to the cells (viability decreased to 89, 59 and 50% with PGA, concentrations of 10, 15 and 30 ,.g ml-', respectively).
After co-culturing with MT-2 cells, CBL usually passed through a growth crisis within the first 2-3 weeks of coculture. After this period, infected cells became predominant and, approximately 12 weeks p.i., apparently immortalised and occasionally independent of IL-2. Depending on different donors, the proliferation rate of infected CBL in some experiments increased already in the second week p.i., without going through a growth crisis.
Addition of 4 itg ml-' every 4 days of either PGA, or di-M-PGA2 to CBL/MT-2 co-culture resulted in a remarkable dose-dependent inhibition of the late CBL proliferation and prevented the selection of immortalised HTLV-I + clones (Table I and Figure 1 ). In six separate CBL/MT-2 co-cultures tested, PGA-treated CBL survived for 4 weeks in the IL-2 enriched medium at levels comparable with normal non-infected controls and within the sixth week practically all cells died as expected for normal CBL (Table I ). The kinetics of 'H-thymidine incorporation paralleled the patterns of cell growth, showing no inhibition exerted by PGAs on the minimal proliferation rate of CBL/MT-2 co-cultures within the first week p.i. and a clear-cut inhibition of late CBL proliferation, starting 2 weeks p.i. and resulting in a marked suppression of 'H incorporation 4 weeks p.i. (Figure 2 ).
The effect of PGAs was strictly dependent on multiple treatments. In fact, when PGAs were added only at the onset of the co-culture (time 0) or in the first 2 days (time 0 and CBL/MT-2 + di-M-PGA2 48 h) of co-culture, late CBL proliferation was not impaired. Moreover, in one experiment (shown in Figure 1 ) CBL proliferation was even enhanced by a single PGA treatment and the growth of HTLV-I infected cells appeared actually to be favoured since PGA-treated CBL/MT-2 contained 35% p19 + cells as compared to 10% present in untreated CBL/ MT-2 co-cultures at 8 weeks p.i.
Repeated PGA treatments either did not affect or increased the percentage of p19 + CBL during the first 2 weeks p.i. (Table II) . At later stages of infection (i.e. 4 weeks p.i.) the proportion of p19 + cells in PGA-treated co-cultures was comparable to or lower than in untreated controls. In any case, even in the co-cultures in which p19 expression was increased at 2 weeks p.i., the anti-proliferative effect of repeated PGAs treatment on HTLV-I infected cells was confirmed, since 'immortalised' HTLV-I + clones were detected in controls but not in PGA-treated CBL/MT-2 cocultures.
HTL V-I integration and expression in CBL/MT-2 co-cultures after PGA-treatment The results obtained by dot blot analysis on genomic DNA extracted from co-cultured CBL showed comparable amounts of integrated provirus in PGA-treated and untreated CBL, 2 weeks p.i. (Figure 3 ). Four weeks p.i., no integrated viral DNA was detectable in most PGA-treated CBL/MT-2 cell preparations (data not shown). When virus expression was tested, it was found that the amount of viral RNA was greatly augmented in infected CBL after PGAtreatment, 2 weeks p.i., approaching the amount detected in the 100% p19 + MT-2 cells. No difference in the percentage of p19 + cells was instead found between PGA-treated and untreated CBL in the same experiment (Figure 3) . However, to this enhancement of HTLV-I mRNA in treated CBL there was no corresponding increase of total RNA synthesis, since no significant difference in 3H-uridine incorporation was found when control CBL, CBLMT-2 co-cultures or CBL/ MT-2 PGA-treated co-cultures were compared, up to the third week of co-culture (data not shown). Figure 4 show that the cytotoxicity of effector cells against K562 targets was significantly reduced by PGAs. The cytolytic activity of CBL was marginal against MT-2 cells and PGAs did not show any detectable effect. CBL co-cultured with irradiated MT-2 cells in IL-2 enriched medium were tested for cytotoxicity against K562 and MT-2 targets on day 7 p.i. The results show that: (a) the cytolytic activity of CBL/MT-2 effectors against K562 or MT-2 cells was respectively 40% or 87% lower than noninfected controls ( Figure 5, legend) ; (b) PGAs further inhibited the killing capacity of infected CBL against K562 targets, but slightly enhanced their cytotoxic activity against MT-2 target cells ( Figure 5) .
Cord blood monocytes showed marginal cytotoxic activity against both K562 and MT-2 target cells when tested on day 0 in a 4 h 5'Cr-release assay (Figure 6 ). After I week of culture, monocytes differentiated into macrophages (Mp) and 4. Their cytotoxic capacity against both K562 and MT-2 targets increased markedly and was not affected by PGA treatment (Figure 6 ). Autologous non-adherent mononuclear cells (mostly T lymphocytes), cultured in IL-2 enriched medium for 1 week, showed higher killing activity against both targets as compared to Mp (see Figure 6 , legend Figure) . n killed K562 targets by: whole CBL/MT-2 co-cultures = 2,396; Ly/MT-2 = 5,704; (Ly/MT-2)+ Mgp= 10,000 (in Figure) . n killed MT-2 targets by: whole CBL/MT-2 co-cultures = 228; Ly/MT-2 = 6,552; (Ly/MT-2) + Mp = 7,200 (in Figure) .
PGAs did not modify the cytotoxic activity of these cells admixed with Ly exposed to HTLV-I infection, tested against K562 or MT-2 targets.
Discussion
Infection with HTLV-I, as for other leukaemia viruses, is usually followed by initial target cell proliferation, growth crisis and virus-induced polyclonal hyperplasia of infected cells that might undergo monoclonal selection and be immortalised in vitro (Hahn et al., 1984) or associate with ATL leukaemia in vivo after a variably long latency period (Hahn et al., 1984; Yoshida, 1987) . This early virus-induced proliferation of sensitive target cells can be considered a predisposing condition to stable transformation (Duesberg, 1987) , according with a multistep model of tumorigenesis and under the control of specific host genes (Knudson, 1985 (Santoro, 1987; Santoro et al., 1986; Santoro & Jaffe, 1989) . In particular, the antiproliferative effect of PGAs was dosedependent, reversible depending on the length of treatment and associated with inhibition of protein synthesis and glycosylation (Santoro, 1987; Santoro et al., 1986) .
HTLV-I infection is followed in vitro and in vivo by remarkable alteration of the immune response (De Vecchis et al., 1985; D'Onofrio et al., 1988; Sociu-Foca et at., 1984; Volkman et al., 1985; Yarchoan et al., 1986) and it has been suggested that the indiscriminant helper function of infected T lymphocytes plays a major role in the auto-maintenance of the leukaemic state (Volkman et al., 1985) . These observations suggested the possibility that the effect of PGAs described could be mediated by interaction with the host's immune system challenged by exposure to the virus. The in vitro and possibly in vivo pattern of the first step of HTLV-I infection implies a cell-to-cell virus transmission accompanied by donor-recipient allogeneic interaction, which elicits a Tcell mediated immune response that in turn could restrain HTLV-I infection. Following this initial step, elimination of autologous virus infected cells is strictly dependent on the efficiency of killing by effector monocytic and lymphocytic cells. Mp+ (Ly/MT-2), against MT-2 targets. This finding does not support the hypothesis that immune mechanisms would play a key role in the PGA-induced suppression of the outgrowth of HTLV-I infected clones, potentially capable of inducing CTL responses (Mitsuya et al., 1983) . The transient but remarkable depression of the majority of lymphocyte markers except for M3 antigens in CBL exposed to virus infection is difficult to interpret. However, this occurrence might contribute to an explanation of the failure of potential immunosurveillance mechanisms to control the emergence of the infected clone. The influence of PGA treatment on these parameters was modest, except for M3. In this case PGAs increased or decreased the percentage of M3 positive cells in cultured control CBL or CBL/MT-2 respectively. Studies are in progress to elucidate the role of Mp in the early phase of infection.
In conclusion, the present data suggest that PGAs could play a significant role in controlling HTLV-I infection by non-immunological mechanisms. Further studies are in progress to explore whether PGA treatment combined with immunomodulating agents (i.e. agents capable of antagonising the immune depression that follows the infection with HTLV-I) would improve the efficiency of in vitro control of infection, in the attempt to elaborate experimental protocols for prevention of HTLV-I related disease in seropositive subjects.
